FR2794648B1 - DNA VACCINES FOR PETS AND SPORTS - Google Patents

DNA VACCINES FOR PETS AND SPORTS

Info

Publication number
FR2794648B1
FR2794648B1 FR9907604A FR9907604A FR2794648B1 FR 2794648 B1 FR2794648 B1 FR 2794648B1 FR 9907604 A FR9907604 A FR 9907604A FR 9907604 A FR9907604 A FR 9907604A FR 2794648 B1 FR2794648 B1 FR 2794648B1
Authority
FR
France
Prior art keywords
dna
vaccine
plasmid
nucleotide sequence
cdv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9907604A
Other languages
French (fr)
Other versions
FR2794648A1 (en
Inventor
Laurent Jean Charles Fischer
Le Roux Simona Barzu
Jean Christophe Franc Audonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9907604A priority Critical patent/FR2794648B1/en
Application filed by Merial SAS filed Critical Merial SAS
Priority to DE60045685T priority patent/DE60045685D1/en
Priority to CA2375320A priority patent/CA2375320C/en
Priority to ES00940474T priority patent/ES2362347T3/en
Priority to PL352212A priority patent/PL210451B1/en
Priority to PCT/FR2000/001592 priority patent/WO2000077043A2/en
Priority to RU2002100211/13A priority patent/RU2283867C2/en
Priority to AT00940474T priority patent/ATE499947T1/en
Priority to AU55405/00A priority patent/AU782154C/en
Priority to EP00940474A priority patent/EP1185662B1/en
Priority to CZ20014392A priority patent/CZ20014392A3/en
Priority to KR1020017015911A priority patent/KR100768114B1/en
Priority to JP2001503899A priority patent/JP2003502345A/en
Priority to DK00940474.0T priority patent/DK1185662T3/en
Priority to NZ515993A priority patent/NZ515993A/en
Priority to BRPI0011732-3A priority patent/BR0011732B1/en
Priority to ARP000102879A priority patent/AR024334A1/en
Publication of FR2794648A1 publication Critical patent/FR2794648A1/en
Priority to ZA200110052A priority patent/ZA200110052B/en
Publication of FR2794648B1 publication Critical patent/FR2794648B1/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

FIELD: gene engineering, virology, veterinary. ^ SUBSTANCE: invention relates to DNA-vaccine against canine distemper virus (CDV). Said vaccine includes at least one DNA-plasmid and cationic lipid containing ammonium salt of formula represented in claim 1 as adjuvant. DNA-plasmid also contains and expresses in host-cells nucleotide sequence encoding CVD immunogene. Nucleotide sequence contains deletion of site, encoding transmembrane domain. Polyvalent vaccine, containing such DNA-vaccine and immunogenic composition containing such DNA-plasmid also are disclosed. ^ EFFECT: new vaccine for vaccination of dogs against CDV. ^ 41 cl, 28 dvg, 3 tbl, 14 ex
FR9907604A 1999-06-10 1999-06-10 DNA VACCINES FOR PETS AND SPORTS Expired - Lifetime FR2794648B1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR9907604A FR2794648B1 (en) 1999-06-10 1999-06-10 DNA VACCINES FOR PETS AND SPORTS
JP2001503899A JP2003502345A (en) 1999-06-10 2000-06-08 DNA vaccine for pet or sports animals
CA2375320A CA2375320C (en) 1999-06-10 2000-06-08 Dna vaccines for pets or for animals used in sports
PL352212A PL210451B1 (en) 1999-06-10 2000-06-08 DNA vaccines for domestic and sports animals
PCT/FR2000/001592 WO2000077043A2 (en) 1999-06-10 2000-06-08 Dna vaccines for pets and sport animals
RU2002100211/13A RU2283867C2 (en) 1999-06-10 2000-06-08 Dna-vaccine (variants) and immunogenic composition against canine distemper
AT00940474T ATE499947T1 (en) 1999-06-10 2000-06-08 DNA VACCINES FOR DOGS
AU55405/00A AU782154C (en) 1999-06-10 2000-06-08 DNA vaccines for pets and sport animals
DK00940474.0T DK1185662T3 (en) 1999-06-10 2000-06-08 DNA vaccines for dogs
CZ20014392A CZ20014392A3 (en) 1999-06-10 2000-06-08 ADN vaccines for pets and sport animals
DE60045685T DE60045685D1 (en) 1999-06-10 2000-06-08 DNA VACCINES FOR DOGS
ES00940474T ES2362347T3 (en) 1999-06-10 2000-06-08 DNA VACCINE FOR DOGS.
EP00940474A EP1185662B1 (en) 1999-06-10 2000-06-08 Dna vaccines for dogs
NZ515993A NZ515993A (en) 1999-06-10 2000-06-08 DNA vaccines for pets and sport animals
BRPI0011732-3A BR0011732B1 (en) 1999-06-10 2000-06-08 DNA VACCINES FOR COMPANY AND SPORT ANIMALS
KR1020017015911A KR100768114B1 (en) 1999-06-10 2000-06-08 Dna vaccines for pets and sport animals
ARP000102879A AR024334A1 (en) 1999-06-10 2000-06-12 DNA VACCINES FOR COMPANY AND SPORTS ANIMALS
ZA200110052A ZA200110052B (en) 1999-06-10 2001-12-06 DNA vaccines for pets and sport animals.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9907604A FR2794648B1 (en) 1999-06-10 1999-06-10 DNA VACCINES FOR PETS AND SPORTS

Publications (2)

Publication Number Publication Date
FR2794648A1 FR2794648A1 (en) 2000-12-15
FR2794648B1 true FR2794648B1 (en) 2003-03-07

Family

ID=9546856

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9907604A Expired - Lifetime FR2794648B1 (en) 1999-06-10 1999-06-10 DNA VACCINES FOR PETS AND SPORTS

Country Status (7)

Country Link
AT (1) ATE499947T1 (en)
DE (1) DE60045685D1 (en)
DK (1) DK1185662T3 (en)
ES (1) ES2362347T3 (en)
FR (1) FR2794648B1 (en)
RU (1) RU2283867C2 (en)
ZA (1) ZA200110052B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197612A1 (en) * 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CN113943354B (en) * 2021-10-11 2022-09-06 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) Recombinant feline herpesvirus gB protein antigen and application thereof in antibody diagnosis and vaccine preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0826063A1 (en) * 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
AU2520197A (en) * 1996-04-29 1997-11-19 Riccardo Wittek Polynucleotide vaccine against canine distemper
FR2751227B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST CANINE CONDITIONS, ESPECIALLY RESPIRATORY AND DIGESTIVE CONDITIONS
FR2751226B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES
FR2751223B1 (en) * 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
WO1998040499A1 (en) * 1997-03-10 1998-09-17 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purposes

Also Published As

Publication number Publication date
ZA200110052B (en) 2002-10-10
DK1185662T3 (en) 2011-06-20
ATE499947T1 (en) 2011-03-15
ES2362347T3 (en) 2011-07-01
RU2283867C2 (en) 2006-09-20
FR2794648A1 (en) 2000-12-15
DE60045685D1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
KR100620302B1 (en) Polynucleotide vaccine formula for treating dog diseases, particularly respiratory and digestive diseases
RU2305559C2 (en) Porcine vaccine against porcine respiratory and reproductive pathologies
EP0936922B1 (en) Polynucleotide vaccine formula for treating horse diseases
Hu et al. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein
ATE272410T1 (en) ADJUVANT COMPOSITIONS FOR INCREASE THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES
PL189184B1 (en) Polynucleotidic vaccine for cattle for intracutaneous administration
EA200301323A1 (en) SINGLE-TIME VACCINATION MYCOPLASMA HYOPNEUMONIAE
Park et al. Cloning and further sequence analysis of the spike gene of attenuated porcine epidemic diarrhea virus DR13
EA200301324A1 (en) MYCOPLASMA BOVIS VACCINE AND METHODS OF REDUCING PNEUMONIA IN ANIMALS
FI3244920T3 (en) Foot-and-mouth disease vaccine
RU2012119494A (en) ISOLATION OF VIRUS RELATED TO PARVOVIRUS-2 DOGS, FROM RACON
Zou et al. Live attenuated vaccine based on duck enteritis virus against duck hepatitis A virus types 1 and 3
Seo et al. Protection of flounder against hirame rhabdovirus (HIRRV) with a DNA vaccine containing the glycoprotein gene
BRPI0813313A8 (en) RECOMBINANT RACUM POXVIRUS VECTOR, RECOMBINANT RABIES VACCINE, METHODS FOR INDUCING AN IMMUNOPROTECTIVE RESPONSE TO RABIES IN A MAMMAL, AND FOR PRODUCING A RECOMBINANT RACUM POXVIRUS VECTOR, AND, PLASMID PFD2003-GPV-PV.
DE69233270D1 (en) Subunit vaccine against dog coronavirus
FR2794648B1 (en) DNA VACCINES FOR PETS AND SPORTS
Baron et al. Expression in cattle of epitopes of a heterologous virus using a recombinant rinderpest virus
WO2001052888A3 (en) Improved dna vaccines for production-type animals
ES2643031T3 (en) Rhipicephalus Tick Vaccine
Yuan et al. Antibody study in canine distemper virus nucleocapsid protein gene-immunized mice
DK0778894T3 (en) Vaccine against infectious feline peritonitis
MX2009013030A (en) Raccoon poxvirus expressing genes of feline antigens.
FR2809960B1 (en) ADJUVANT COMPOSITION OF THE IMMUNE RESPONSE COMPRISING FHA PROTEIN OR A FRAGMENT OF FHA PROTEIN IN FREE FORM, AND IMMUNOGENIC OR VACCINE COMPOSITION CONTAINING SUCH ADJUVANT COMPOSITION
JP2002360285A5 (en)
BR0110791A (en) Composition, methods for inducing an individual immune response against an immunogen, modulating an individual's immune system and immunizing an individual against a live attenuated pathogen, recombinant vaccine, and pathogen

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20